Have a feature idea you'd love to see implemented?
Let us know!
VIR Vir Biotechnology Inc
Price (delayed)
$10.225
Market cap
$1.41B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.92
Enterprise value
$1.24B
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are
Highlights
The debt has contracted by 18% YoY
VIR's gross margin is up by 6% year-on-year
The EPS rose by 13% year-on-year but it has declined by 9% since the previous quarter
The net income has increased by 11% year-on-year but it has declined by 10% since the previous quarter
VIR's revenue is down by 34% YoY
The company's gross profit fell by 30% YoY
Key stats
What are the main financial stats of VIR
Market
Valuations
Earnings
Shares outstanding
137.72M
Market cap
$1.41B
Enterprise value
$1.24B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.13
Price to sales (P/S)
17.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.82
Revenue
$78.62M
Gross profit
$77.66M
Net income
-$533.34M
EBIT
-$539.19M
EBITDA
-$517.45M
Free cash flow
-$472.16M
Per share
Balance sheet
Liquidity
EPS
-$3.92
EPS diluted
-$3.92
Free cash flow per share
-$3.46
Book value per share
$9.08
Revenue per share
$0.58
TBVPS
$10.7
Total assets
$1.5B
Total liabilities
$257.63M
Debt
$93.41M
Equity
$1.24B
Working capital
$930M
Debt to equity
0.08
Current ratio
8.94
Quick ratio
8.57
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
-658.2%
Gross margin
98.8%
Net margin
-678.4%
Operating margin
-774.7%
Return on assets
-31%
Return on equity
-36.7%
Return on invested capital
-38.1%
Return on capital employed
-39%
Return on sales
-685.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIR stock price
How has the Vir Biotechnology stock price performed over time
Intraday
-2.8%
1 week
29.59%
1 month
37.25%
1 year
-1.4%
YTD
39.31%
QTD
39.31%
Financial performance
How have Vir Biotechnology's revenue and profit performed over time
Revenue
$78.62M
Gross profit
$77.66M
Operating income
-$609.03M
Net income
-$533.34M
Gross margin
98.8%
Net margin
-678.4%
The net margin has contracted by 34% YoY and by 11% from the previous quarter
VIR's revenue is down by 34% YoY
The company's operating margin fell by 32% YoY and by 8% QoQ
The company's gross profit fell by 30% YoY
Growth
What is Vir Biotechnology's growth rate over time
Valuation
What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
1.13
P/S
17.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.82
The EPS rose by 13% year-on-year but it has declined by 9% since the previous quarter
VIR's price to book (P/B) is 69% lower than its 5-year quarterly average of 3.7 but 41% higher than its last 4 quarters average of 0.8
Vir Biotechnology's equity has decreased by 26% YoY and by 13% from the previous quarter
The price to sales (P/S) is 56% lower than the 5-year quarterly average of 40.4 but 16% higher than the last 4 quarters average of 15.3
VIR's revenue is down by 34% YoY
Efficiency
How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on assets has decreased by 26% YoY and by 19% QoQ
The return on sales has declined by 24% year-on-year and by 10% since the previous quarter
Vir Biotechnology's return on equity has decreased by 19% QoQ and by 15% YoY
The return on invested capital rose by 16% year-on-year but it has declined by 15% since the previous quarter
Dividends
What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIR.
Financial health
How did Vir Biotechnology financials performed over time
The company's total liabilities fell by 30% YoY but it rose by 9% QoQ
The current ratio has contracted by 29% from the previous quarter and by 17% YoY
The debt is 92% less than the equity
Vir Biotechnology's equity has decreased by 26% YoY and by 13% from the previous quarter
The debt has contracted by 18% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.